A further description of risks and uncertainties can be found in Pfizers Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned Risk Factors and Forward-Looking Information and Factors That May Affect Future Results, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S
JInfectDis 2001][Akang EN
Product added (0 items) Explore and choose your skincare essentials
Only 13 state Medicaid programs nationwide cover GLP-1s for obesity as of January 2026, down from 16 in October 2025
Here are some potential benefits of switching: More and faster weight loss Better blood glucose control, especially when weight loss has plateaued Drug availability, as tirzepatide may be easier to find right now Lower cost, with tirzepatide being about $300 less per month without insurance Risks and Potential Drawbacks of Switching Switching from semaglutide to tirzepatide can come with potential risks and drawbacks beyond just the common side effects
Consider fibre supplements if you cant meet needs through diet